Review article

Natriuretic Peptides in Cardiovascular Diseases

MARIusz PIECHOTA1, MACIEJ BANACH2*, ANNA JACOŃ3 and JACEK RYSZ4

1Department of Anaesthesiology and Intensive Care Unit, Boleslaw Szarecki University Hospital No. 5 in Łódź, Medical University in Łódź, Poland,
2Department Cardiology, 1st Chair of Cardiology and Cardiac Surgery, University Hospital No. 3 in Łódź, Medical University in Łódź, Poland,
3Department of Health Protection Policy, Medical University of Łódź, Poland
42nd Department of Family Medicine, University Hospital No. 2 in Łódź, Medical University in Łódź, Poland

Abstract: The natriuretic peptide family comprises atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide (DNP), and urodilatin. The activities of natriuretic peptides and endothelins are strictly associated with each other. ANP and BNP inhibit endothelin-1 (ET-1) production. ET-1 stimulates natriuretic peptide synthesis. All natriuretic peptides are synthesized from polypeptide precursors. Changes in natriuretic peptides and endothelin release were observed in many cardiovascular diseases: e.g. chronic heart failure, left ventricular dysfunction and coronary artery disease.

Key words: Atrial natriuretic peptide, Brain natriuretic peptide, C-type natriuretic peptide, Dendroaspis natriuretic peptide, Urodilatin, Endothelin-1

* Author for correspondence: Department of Cardiology, Medical University of Łódź, Sterlinga 1/3, 91-425 Łódź, Poland, tel/fax: +48 42 6364 471, e-mail: m.banach@termedia.pl

Abbreviations used: ACTH – adrenocorticotropic hormone; ANP – atrial natriuretic peptide; AVP – arginine vasopressin; BNP – brain natriuretic peptide; CHF – chronic heart failure; CNP – C-type natriuretic peptide; cGMP – cyclic guanosine monophosphate; DNP – dendroaspis natriuretic peptide; ET – endothelin; FGF – fibroblast growth factor; NO – nitric oxide; NYHA – New York Heart Association; PAI – plasminogen activator inhibitor; PGDF – platelet derived growth factor; TGF – transforming growth factor; TIMP – tissue inhibitor of matrix metalloproteinase; TNF – tumor necrosis factor
INTRODUCTION

The natriuretic peptide family comprises atrial natriuretic peptide (ANP; A-type natriuretic peptide), brain natriuretic peptide (BNP; B-type natriuretic peptide), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide (DNP), and urodilatin. Atrial natriuretic peptide was the first to be identified, in 1981 [1]. In 1984, Kangawa and Matsuo published the full amino acid sequence of human ANP [2]. ANP is a peptide made up of 28 amino acids, and it is first secreted by the heart atria. Brain natriuretic peptide was identified in 1988 [3, 4]. It was primarily isolated from the pig brain, and thus was called brain natriuretic peptide. However, it was soon found that BNP is synthesized in the ventricular myocytes. In humans, this peptide is made up of 32 amino acids. In 1990, C-type natriuretic peptide was isolated from the pig brain. It is produced mainly in the central nervous system and vessels [5, 6]. In humans, the CNP chain consists of 22 amino acids [7]. D-type natriuretic peptide was isolated from the venom of the green mamba. Structurally, it is similar to ANP, BNP and CNP [8, 9]. In humans, DNP is present in the atrial cells and the plasma [10]. Urodilatin is also included in the family of natriuretic peptides. It is a 32-amino acid paracrine hormone that was isolated from human urine in 1988. Its structure is nearly identical to that of ANP; the difference is the 4 additional amino acids in the N-terminal fragment, urodilatin. This is not surprising, because ANP and urodilatin are formed as the results of cleavage of the same peptide: proANP (1-126). Urodilatin is produced by the renal tubule cells and acts exclusively in the kidneys. Some authors consider it to be a renal form of ANP.

A peptide with the function of constricting the blood vessels was first discovered by Hickey et al. [11]. A few years later, the sequence of this peptide was determined [12]. Called endothelin (ET), it appeared to be identical in humans, dogs, rats and pigs.

The activities of natriuretic peptides and endothelins are relatively strictly associated with each other. ANP and BNP are peptides that inhibit endothelin-1 production. On the other hand, ET-1 stimulates natriuretic peptide synthesis [13]. This specific self-control is found in many diseases of the circulatory system. In pathological conditions, the predominance of one of these systems in patients can be identified, and sometimes counteracted effectively, after the determination of the plasma concentrations of the defined natriuretic peptides and endothelins.

NATRIURETIC PEPTIDES

All natriuretic peptides are synthesized from polypeptide precursors. ANP, BNP and CNP have very similar structures. Each of them has a ring consisting of 17 amino acids, of which 11 are identical [14]. Urodilatin and ANP have an identical ring (Fig. 1).
Atrial natriuretic peptide is first synthesized in the atrial cells. A low concentration of ANP was also found in the ventricular cells and kidneys. However, compared to the myocardium, the ANP concentration in the kidney is negligible. ANP is synthesized in the form of a biologically inactive propeptide, proANP, which consists of 126 amino acids. This peptide undergoes cleavage by endoprotease (membrane serine protease) in the endoplasmic reticulum, into the biologically active C-terminal fragment, proANP (99-126) (also called alpha-ANP) (1-98). Alpha ANP is rapidly eliminated from the plasma; its half-life is 3-4 minutes. The Nt-pro-ANP half-life is significantly longer (60-120 min).

Brain natriuretic peptide is mainly synthesized in the ventricular cells. BNP derives from the prepro-BNP precursor consisting of 134 amino acids. After cleavage, prepro-BNP splits into a 108-amino acid pro-BNP (1-108) and a 26-amino acid signal peptide (109-134). In turn, pro-BNP splits into the biologically active 32-amino acid C-terminal fragment, BNP (77-108), and the inactive 76-amino acid N-terminal fragment, Nt-proBNP (1-76) [15-19]. BNP has a half-life of about 20 minutes. The half-life of Nt-pro-BNP is significantly longer (60-120 min).

C-type natriuretic factor is found in the central nervous system, the endothelial cells and in low concentrations in the blood plasma. It plays the role of the
paracrine hormone. CNP is produced from the precursor pro-CNP as the result of cleavage by endoprotease. The atrial and ventricular cells are potent stimuli of ANP and BNP release. Both ANP and BNP are stored in granules and secreted via regulatory pathways from the atria. They are also secreted via the constitutive pathway from the ventricles. ANP is immediately released from atrial cell granules, which, coupled with its very short half-life, results in dynamic changes in its concentration in the blood. The secretion of BNP is mainly from the left ventricular cardiomyocytes, is controlled at the transcription level, and requires longer-lasting stimuli. An increased BNP concentration in the blood remains for a significantly longer time than an increased ANP concentration.

Tachycardia is a factor that intensifies natriuretic peptide synthesis. Glycocorticosteroids, thyroid hormones, endothelin-1 and angiotensin II also increase this synthesis. Endothelin-1 and angiotensin II intensify the synthesis independently of their haemodynamic activity. CNP secretion is regulated by growth factors and cytokines, mainly by TNF-α, interleukin-1, basic fibroblast growth factor, and transforming growth factor β. Increased CNP secretion is observed as the result of tissue damage or hypoxia.

Natriuretic peptides are ligands for three types of natriuretic receptors: type-A, type-B and type-C. These receptors are localized on the target cell surfaces. Type-A and type-B receptors have two extracellular domains binding the ligand, and two intracellular domains containing guanyl cyclase and kinase, which condition the formation of cGMP (cyclic guanosine monophosphate). Type-A and type-B receptors are responsible for the majority of the known biological activities of natriuretic peptides [20, 21]. Type-C receptors clear the natriuretic peptide from the circulation (clearance receptors). ANP and BNP mainly bind with type-A receptors, and CNP with type-B receptors [22]. ANP has the highest affinity to type-A receptors. It also shows a high affinity to type-C receptors. Natriuretic peptides are cleared from the circulation with the help of a clearance receptor (type-C receptor), and thanks to endopeptidases present on the surfaces of the epithelial cells, smooth muscles, myocytes, renal epithelium and fibroblasts.

ANP and BNP are secreted from cardiac myocytes in response to atrial or ventricular wall stretch. The activity of ANP and BNP is similar. They increase glomerulal filtration and natriuresis, suppressing sodium reabsorption, they relax the vessels’ smooth musculature causing a decrease in the cardiac preload and afterload and a decrease in blood arterial pressure. They reduce the noradrenergic and renin-angiotensin-aldosterone system activities. Besides their renal and vascular effects, natriuretic peptides exert effects on the suprarenal cortex, decreasing the secretion of mineralocorticoids and glicocorticoids.

ANP hipotensive activity lies in the relaxation of the resistance vessels, mainly the precapillary arterial vessels and, to a lesser degree, the extracapillary venous vessels. Suppressing venous return, ANP reduces blood flow to the heart and decreases cardiac output leading to a decrease in arterial pressure. However, in
patients with chronic heart failure (CHF), the infusion of ANP significantly increased the stroke volume index. The permeability of endothelium to plasmic fluid increases under the effect of ANP, causing its outflow from vessels to the extravascular space and thus increasing the hematocrit and plasma protein concentration. Then, hypovolemia occurs, which is intensified by the simultaneous natriuretic activity of ANP [23]. ANP is assumed to play an important role in organism adaptation to an acute elevation of the plasma volume, increasing sodium and water excretion, but it is less important in conditions of chronic hypervolemia. Atrial natriuretic peptide does not exert any significant effect on the renal blood flow, but at higher plasma concentrations, it may cause blood redistribution to deeper layers of the cortex and to the renal medulla. ANP has a relaxing effect on the preglomerular vessels, which may increase glomerular filtration and decrease the sensitivity of tubulo-glomerular feedback counteracting angiotensin II.

The data indicated the presence and important role in the body fluid homeostasis of brain atrial natriuretic peptide (ANP) in all the vertebrate species examined. The peptide is localized in neurons in the hypothalamic and brain stem areas involved in body fluid volume and blood pressure regulation, and its receptors are located in the regions that contain the peptide. Most, if not all of the actions of ANP are mediated by the activation of particulate guanylyl cyclase with the generation of guanosine 3',5'-cyclic monophosphate, which mediates its actions in the brain as in the periphery. Although atrial stretch releases ANP from cardiac myocytes, the experiments indicate that the response to acute blood volume expansion is markedly reduced after the elimination of neural control. Volume expansion distends baroreceptors in the right atria, carotid-aortic sinuses, and kidneys, altering the afferent input to the brain stem and hence the hypothalamus, resulting via ANPergic neurons in the hypothalamus in the stimulation of oxytocin release from the neurohypophysis that circulates to the right atrium to stimulate ANP release. The ANP circulates to the kidney and induces natriuresis. Atrial natriuretic peptide also induces vasodilatation, compensating rapidly for increased blood volume by increased vascular capacity. Atrial natriuretic peptide released into hypophysial portal blood vessels inhibits the release of adrenocorticotropic hormone (ACTH), thereby decreasing aldosterone release and enhancing natriuresis. Furthermore, the ANP neurons inhibit AVP (arginine vasopressin) release, leading to diuresis and decreased ACTH release. The activation of hypothalamic ANPergic neurons via volume expansion also inhibits water and salt intake. These inhibitory actions may be partially mediated via ANP neurons in the olfactory system altering salt taste. Atrial natriuretic peptide neurons probably also alter fluid movement in the choroid plexus and in other brain vascular beds. Therefore, brain ANP neurons play an important role in modulating not only the intake of body fluids, but also their excretion to maintain body fluid homeostasis [24]. The natriuretic and hypotensive effect of BNP is more pronounced than that of ANP [25]. Both peptides similarly suppress the renin activity of the plasma and
Moreover, BNP exerts myocardial relaxing activity, and antiproliferative and antifibrinolytic activity [27, 28]. BNP has a direct effect on the cardiac fibroblasts by inhibiting fibrotic responses via extracellular signal-related kinase signaling. BNP opposes TGF-β-regulated genes related to fibrosis (collagen 1, fibronectin, CTGF, PAI-1, and TIMP3), myofibroblast conversion (α-smooth muscle actin 2 and non-muscle myosin heavy chain), proliferation (PDGFA, IGF1, FGF18, and IGFBP10), and inflammation (COX2, IL6, TNFα-induced protein 6, and TNF superfamily, member 4) [29].

CNP, produced by the endothelial cells, is thought to play an important role in the local dilation of vessels. Unlike other natriuretic peptides, CNP acts only locally. It affects the smooth muscles of both the venous and arterial vessels. CNP does not demonstrate natriuretic properties.

Urodilatin is an important regulator of renal sodium excretion. Natriuretic peptides, besides their direct vasodilating effect, also exert an indirect prohypotensive activity inhibiting the vasoconstricting effect of noradrenaline, angiotensin II and vasopressin [30]. Furthermore, they weaken the angiotensin II and vasopressin central pressor effect and the central stimulation of the sympathetic system.

The level of Nt-pro ANP circulating in the plasma is more stable than that of the pulsatively secreted alpha-ANP. Nt-pro ANP better reflects the chronic level of ANP secretion, whereas alpha-ANP reflects its level at a given moment. Nt-pro ANP is more useful in medium- and long-term diagnostics and prognosis [31]. Withthaut et al., investigating among other things the level of ANP, obtained mean ANP concentrations in healthy subjects of 14.9 ± 1.2 pg/ml [32]. In the studies of Hoffmann et al., mean concentration of Nt-proANP measured with the ELISA method in healthy persons was 1404 pmol/l.

Under physiological conditions, the concentration of BNP in the blood serum is low. Maisel et al. observed that the level of BNP depends on the patient’s age and race and not on the patient’s gender [33]. The suggested range of normal values of BNP concentration is 0.5-30 pg/ml (0.15-8.7 pmol/l) [34]. In the immunoenzymatic method (Biomedia), the reference values of Nt-pro BNP in healthy subjects are < 600 pg/ml (250 pmol/ml). In the studies of Cosin et al., the Nt-pro BNP level was found to depend on the patient’s age and gender [35].

The range of normal blood BNP and Nt-pro BNP concentration depends on the method of determination and even on the producer of the reagents used. The form of BNP found in the plasma is of significant importance. Determining the Nt-pro BNP level is recommended for risk assessment because of its more stable form and longer half-life. However, a biologically active BNP fragment of a markedly shorter half-life may be useful in monitoring the clinical condition over the course of therapy [36].
ENDOTHELINS

Endothelins are 21-amino acid peptides synthesized by a wide variety of cell types, above all by the vascular wall cells and in the brain, kidneys and endocrine glands [37-40]. So far, 3 peptides coded by 3 different genes have been identified: endothelin-1 (ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3) [41]. Endothelin-1 is formed from a polypeptide precursor – big ET-1. Big ET-1 consists of 38 amino acids (1-38). After cleavage, ET-1 (1-21) and the C-terminal fragment (22-38) are formed [42]. ET-1’s vasoconsticting potency is 140 times higher than that of big ET-1 [43].

Endothelin-1 structure and function is the best understood. Only two amino acids differentiate endothelin-2 from ET-1 (6-Trp, 7-Leu). Endothelin-2 effector activity does not differ from that of ET-1. Six amino acid residues (2-Thr, 4-Phe, 5-Thr, 6-Tyr, 7-Lys, 14-Tyr) differentiate ET-3 from ET-1. Endothelin-3 also demonstrates a different affinity than ET-1 to receptors, and thus a different function in the organism’s physiology [44]. Adrenaline, angiotensin II, vasopressin, thrombin, insulin, interleukin 1, platelet-derived growth factor (PGDF), TNF-α and epidermal growth factor (EGF) are among the other factors stimulating endothelin secretion.

ET-A and ET-B are two types of receptor that are bound with G proteins and that mediate endothelin action [45]. The activation of ET-A results in an increase in the activity of phospholipase C, phospholipase D and sometimes phospholipase A2. Thus, it results in the elevation of the cytoplasm calcium ion concentration, yielding a vasoconstrictive effect. The activation of the receptors of ET-B and its recognized subtypes (endothelial ET-B1 and muscular ET-B2) causes an increase in the production of compounds which relax the vascular smooth muscles (e.g. nitric oxide or adrenomedulline), and an increase in endothelin gene expression, locally stimulating its own synthesis. ET-1 secreted by epithelial cells activates both types of receptor [46]. The induction of endothelial ET-B receptors causes vascular relaxation through the stimulation of NO synthesis activity with a subsequent increase in guanylyl cyclase and increased cGMP release. Furthermore, through the stimulation of prostacycline synthesis, it results in the activation of adenyl cyclase and increased cAMP release. These simultaneous processes lead to a decrease in the intracellular calcium ion concentration. However, the vasoconstrictive effect predominates in the vessels [47]. In the circulatory system, ET-A receptors are found in smooth muscle and cardiomyocyte cells, whereas ET-B receptors are found in endothelial and muscular cells [48].

Endothelin-1 acts both as a paracrine-autocrine hormone strongly constricting vessels and as a mitogenic hormone released by the vascular endothelium [49]. Thusfar, studies have demonstrated a strong effect of endothelins on coronary, cerebral, renal and mesenteric microcirculation. In the heart, endothelin-1 is a potent constrictor of coronary vessels [50]. An effect on heart rate has also been observed. Intravenous administration of ET-1
leads to spontaneous slight tachycardia associated with a temporary drop in arterial pressure, followed by long-lasting bradycardia evoked by stimulation of baroreceptors by increasing arterial pressure. This effect predominates despite the direct positive inotropic and chronotropic activity that ET-1 exerts on the cardiomyocytes. ET-2 and ET-3 demonstrate similar inotropic activity; however, it is significantly weaker than that of ET-1 [51, 52].

Under the conditions of activated shear stress caused by the elevated afterload, and under the effect of angiotensin II, the secretion of endothelins in the myocardium increases. Blocking angiotensin II production with convertase inhibitors results in ET-1 secretion inhibition [53]. By increasing aldosterone secretion, endothelin participates with angiotensin II in cardiac muscle fibrosis [54]. The haemodynamic effect of ET-1 on kidneys leads to an increase in sodium resorption [55, 56]. ET-1 potentiates the secretion of natriuretic peptides and stimulates cardiomyocyte and fibroblast proliferation.

The reference values of ET-1 have not been determined precisely for healthy subjects via the immunoenzymatic method. It is recommended that each laboratory should determine their own reference levels. Biomedica reports that in 70 healthy subjects the median serum ET-1 concentration obtained by this method was 0.65 pg/ml (0.26 fmol/ml).

**NATRIURETIC PEPTIDES IN CIRCULATORY SYSTEM DISEASES**

Increased ANP release was observed in patients with chronic heart failure, left ventricular dysfunction or coronary artery disease. In some clinical situations, an increase in BNP concentration was observed. The following are included: aortic stenosis, chronic heart failure, left ventricular dysfunction or hypertrophy, hypertension, ischemic heart disease, pulmonary embolism, primary pulmonary hypertension, myocarditis, heart transplant rejection, arrhythmogenic right ventricular dysplasia with decreased ejection fraction, Kawasaki’s disease, renal failure, hyperaldosteronism, Cushing’s syndrome, and decompensated cirrhosis. Advanced age and female gender were also observed to be associated with increased BNP. However, lower concentrations of BNP may result from the coexistence of mitral stenosis, dehydration, therapy with diuretics or angiotensin-converting enzyme inhibitors [57-61]. Increased CNP secretion is observed as the result of tissue damage or hypoxia and in the course of chronic renal failure.

Endothelins are thought to participate in the pathogenesis of: arterial hypertension, pulmonary hypertension, dilated cardiomyopathy, idiopathic pulmonary fibrosis, asthma, food allergies, and cerebral vasospasm after subarachnoid haemorrhage [62-65].

**HEART FAILURE**

An infusion of atrial ANP significantly decreased pulmonary capillary wedge pressure and increased the stroke volume index in all of the patients with CHF.
Although it decreased pulmonary capillary wedge pressure, it caused no significant change in the stroke volume index in the patients without CHF. Concomitant significant reductions in total systemic resistance were observed in both groups of patients. The ANP infusion significantly increased the urine volume, the excretion of sodium, and the endogenous creatinine clearance in patients without CHF. In patients with CHF, it showed a tendency to increase all these variables, but the urine volume did not correlate with the reduction in pulmonary capillary wedge pressure. Although no significant difference was observed in the decrement of the plasma aldosterone concentration in the patients with and without CHF, the ANP infusion also decreased the plasma aldosterone concentrations. These findings indicate that the ANP infusion improves left ventricular function in patients with CHF, and suggest that this improvement mainly results mainly from the vasodilating activity of ANP [66]. Brain natriuretic peptide is of prognostic importance in cardiovascular diseases [67, 68]. In patients with heart failure, serum BNP concentrations are found to increase proportionally to the severity of the clinical condition evaluated according to the New York Heart Association (NYHA) classification, and may be 25 times higher than the values in subjects without this pathology [69]. In studies by Cosin et al., authors observed that NT-proBNP correlates with the patient’s condition in NYHA classification [70]. In the studies of McDonagh et al., the plasma level of the NT-pro BNP concentration was 15.2 ± 14.2 pg/ml in healthy subjects, while in patients with chronic heart failure, it increased on average 45-fold to 691 ± 49 pg/ml [71]. In the studies of Dao et al., in patients with chronic heart failure, the mean values of serum BNP were: 95 pg/ml (NYHA I), 221 pg/ml (NYHA II), 459 pg/ml (NYHA III) and 1006 pg/ml (NYHA IV) as compared to 12 pg/ml found in healthy subjects [72]. BNP at the cut-off point of 80 pg/ml demonstrates a very high sensitivity and specificity in the diagnosis of chronic heart failure. The predictive value of BNP concentrations of less than 80 pg/ml for the diagnosis of chronic heart failure was 98% [73]. Cowie et al., based on a study of 122 patients, showed that BNP concentrations exceeding 76.8 pg/ml (22.2 pmol/l) allow the diagnosis of chronic heart failure with 97% sensitivity and 84% specificity [74]. Berger et al. confirmed the importance of BNP concentration as a predictive factor of sudden death in the course of chronic heart failure [75]. Observing 452 patients with an ejection fraction < 35% for 3 years, they found out that BNP concentration was the only independent indicator of the risk of sudden death. Their accepted cut-off value of 130 pg/ml is similar to the 80 pg/ml value applied by Dao. Tsutamoto et al. [76] demonstrated on the basis of a group of patients with CHF that the increase in plasma BNP concentration by 10 pg/ml was associated with a 3% risk of death in the period of further observation.

So far, the determination of one limiting value of BNP confirming or excluding chronic heart failure has been unsuccessful. Values between 80 and 130 pg/ml (the decisive value) are most frequently mentioned. Elevated BNP concentrations enable the precise diagnosis of both systolic and diastolic heart
failure [77]. In the study of Marsel et al., the BNP concentration in patients with left ventricular diastolic dysfunction was $391 \pm 89$ pg/ml, whereas in the group of patients with systolic dysfunction, it was higher: $567 \pm 113$ pg/ml [78]. The plasma BNP concentration was demonstrated to correlate with the value of pulmonary artery wedge pressure and with left ventricular end-diastolic pressure [79-84].

In patients with severe heart failure, the kinetics of natriuretic peptide secretion and excretion is disturbed, which leads to prolongation of the time of retention of these peptides in the plasma and to an increase in the partially degraded fraction of hormones. Thus, the increase in peptide concentration is not equivalent to the increase in hormone activity or to the increase in its plasma secretion because both of these effects depend on other physiological processes. Left ventricular dysfunction is manifested by a deepening imbalance between the system of sodium retention and the mechanisms leading to vasoconstriction and mechanisms of sodium excretion and vasorelaxation. This may be caused by the impairment of the hormone mechanisms associated with the process of sodium excretion caused by the impaired function of the vascular receptors for the system of natriuretic peptides and possibly also by disordered feedback between the plasma concentration of these peptides and their excretion. This mechanism may partly be the cause of the increase in natriuretic peptide concentration and the overlapping effects of the increased secretion and retention of natriuretic peptides making it impossible to easily interpret the mechanisms causing the elevation in concentration [85]. Furthermore, it is assumed that the factors capable of initiating cardiac hypertrophy induce numerous pathways of signal transduction and transcription factors, leading to increased expression of fetal genes in cardiomyocytes and thus the increase of ANP gene promotor activity [86].

BNP concentration demonstrates strict correlation with the class of heart failure according to NYHA. The diagnostic value of insignificantly and moderately elevated BNP concentrations is made difficult by the fact that they may result from, for example, cardiac hypertrophy. However, this measurement seems to be useful in the diagnostics of diastolic heart failure. In subjects with elevated blood pressure and right ventricular structural dysfunction (primary pulmonary hypertension, cor pulmonale, pulmonary embolism, congenital diseases and right ventricular arrhythmogenic dysplasia), BNP concentration increases to a lesser degree than in those with left ventricular dysfunction. BNP concentration appears to be of prognostic value, and as it is suggested in the most recent studies, it can enable the determination of risk of death including sudden death and hospitalization to a higher degree than NYHA class or ejection fraction. The highest values of Nt-pro BNP are observed in left ventricular systolic dysfunction. Elevated values of Nt-pro BNP were observed in patients who had in their history pulmonary oedema or had an ejection fraction < 40% [87].

Determination of BNP and N-terminal BNP concentrations may help in the
qualification of patients with heart failure for transplantation or cardioverter-defibrillator implantation [88, 89].

Hammerer-Lerches et al. carried out studies aiming to estimate the causes of variability observed in natriuretic peptide assays [90]. They compared the diagnostic effectiveness of BNP, Nt-pro BNP and Nt-pro ANP as indicators of cardiac performance in 130 patients with mild forms of left ventricular dysfunction, and simultaneously compared three competing methods for determining these parameters. It appeared that patients with mild left ventricular dysfunction are best identified by BNP and Nt-pro BNP analysis; the obtained diagnostic performance coefficients (AUC, area under curve ROC determining the probability of the correct classification of a patient based on a positive or negative test result) were 0.78 (95% CI: 0.63-0.89) for BNP and 0.75 (95% CI: 0.58-0.87) for Nt-pro BNP. However, the determination of the Nt-pro ANP level demonstrated a significantly lower diagnostic performance (AUC 0.64; 95% CI: 0.48-0.77). We also discovered that patients with isolated left ventricular diastolic dysfunction had a BNP diagnostic performance that was significantly better than in the case of Nt-pro BNP. The cut-off value and diagnostic performance of BNP determination depends on the applied method. Mild left ventricular dysfunction without group differentiation as regards to gender and age was associated with a BNP concentration exceeding 50 ng/l (14 pmol/l). The obtained Nt-pro BNP values differed significantly depending on the test producer. The Nt-proBNP test by Roche Diagnostics correlated significantly better with the results of the functional tests than the Biomedica version, which detected left ventricular dysfunction less successfully. The peptide diagnostic parameters determined by immunochemical methods with the application of a panel of highly specific monoclonal antibodies may present different results because many of these peptides undergoing rapid plasma proteolytic degradation lose epitopes essential for recognizing an analyte by antibodies in the first stage of the reaction.

The results of the mentioned studies are in agreement with the results of the survey on the determination of natriuretic peptide levels in subjects with mild heart failure [91]. The authors of the survey assessed about 12,000 studies devoted to this problem, published in the years 2000-2004. About 7,000 studies directly concerned ANP determination, and 800 BNP determination. 151 studies fulfilled the accepted criteria of credibility. The authors revealed enormous discrepancies in research assumptions, patient selection criteria and even the standards of clinical condition assessment. Therefore, although numerous authors point to the usefulness of natriuretic peptide determinations in screening examinations and in the classification of patients with heart failure, it is currently difficult to determine what examinations could be substituted and when in the diagnostics of heart failure for the determination of natriuretic peptide levels. Similar conclusions concern the application of natriuretic peptide determinations as prognostic factors in patients with heart failure. In various centers, different natriuretic peptides were analysed (ANP, BNP, Nt-pro ANP, Nt-pro BNP,
CNP); these differ in origin, structure and role in the pathophysiological processes. Also, many different immunochemical methods were used varying in the ways of detection of natriuretic peptides.

In 2002, the Working Group on Heart Failure of the European Society of Cardiology recommended that natriuretic peptides be assessed as screening markers of heart failure equally with chest electrocardiograms and radiograms [92]. BNP determination is in the European Society of Cardiology guidelines aiming at the improvement of the diagnosis of chronic heart failure [93].

Patients with high long-term BNP concentrations, despite aggressive treatment, have exceptionally high risk of cardiac events. The effect of the applied drugs on serum BNP concentrations in patients with chronic heart failure was proved in the Valsartan-Heart Failure Trial (Val-HeFT) and the Randomized Aldactone Evaluation Study (RALES). The best prognosis was for the patients with the most significant decrease in BNP concentration (in relation to the initial value), whereas the highest mortality was observed in the group of patients with the highest increase in this concentration [94]. In RALES, the decrease in mortality rate in the group treated with spironolactone was proportional to the decrease in BNP concentration as compared to the initial values. The lack of its evident decrease during effective therapy with a b-adrenolytic drug was puzzling. Troughton et al. demonstrated a lower number of deaths and repeated hospitalizations in a group of patients with chronic heart failure whose treatment (with a diuretic and angiotensin convertase inhibitors) was controlled by determining Nt-pro BNP concentration [95].

Defining the role of BNP in the treatment of patients with chronic heart failure appeared to be equally important. Intravenous administration of BNP was found to improve hemodynamic parameters and to decrease regional sympathetic activity in heart failure [96]. Similarly, intravenous application of recombined human brain natriuretic peptide (nesiritide) to patients with decompensated CHF resulted in a beneficial hemodynamic effect in the form of a cardiac output increase, a decrease in the mean wedged pressure and pulmonary artery pressure, an improvement in the cardiac index and renal flow without an accompanying non-beneficial effect of heart rate increase or the occurrence of other cardiac arrhythmias [97].

Numerous authors emphasize the usefulness of BNP concentration determination in the differentiation of the causes of acute dyspnoea other than chronic heart failure. Based on a study comprising 250 patients, Quyen et al. [98] found that this determination confirmed or excluded acute heart failure as a cause of dyspnoea: the positive prognostic value was 95%, and the negative was 97%. In the Breathing Not Properly Study, performed on 1586 patients who reported to the hospital for sudden dyspnoea, the highest BNP values (675 ± 450 pg/ml) were observed for subjects who presented symptoms caused by an intensification of chronic heart failure. Lower values were found in patients with a history of this disease, but the presented symptoms were non-cardiac (346 ± 390 pg/ml). The lowest BNP concentrations (110 ± 225 pg/ml) were
detected in subjects without heart failure, with a non-cardiac cause of dyspnoea [99]. Decreased BNP concentrations in the course of treatment of acute heart failure were observed to be associated with a good prognosis. Deaths were more frequent among patients in whom, despite the introduced therapy, these concentrations remained unchanged or increased [100, 101].

CNP is found in the endothelium of the heart. It has a very low concentration in the plasma, and elevations in CNP concentration are not associated with congestive heart failure.

**ISCHEMIC HEART DISEASE AND ITS COMPLICATIONS**

B-type natriuretic peptide (BNP, Nt-pro BNP) is also an indicator of myocardial ischemia. Sabatine et al. discovered that transient myocardial ischemia was associated with a rapid increase in BNP concentration, and that this increase was proportional to the severity of the ischemia. A similar relationship was observed in the case of Nt-pro BNP. However, the changes in Nt-pro BNP concentration in response to ischemia were expressed less distinctly [102]. In patients with acute coronary syndrome, BNP is secreted by undamaged cardiomyocytes. The increase in BNP concentration reflects the extensiveness and intensity of myocardial ischemia and accompanying contractility impairment. An elevated concentration of BNP (and Nt-pro BNP) is observed in all forms of acute coronary syndrome.

James et al. assessed 6,809 patients with acute coronary events with non-ST-segment elevation in whom Nt-pro BNP was determined (GUSTO IV study). They found that the annual mortality of patients with an NT-pro BNP of less than 98 pg/ml was 0.4% and with values above 4,634 pg/ml was as high as 27.1% [103].

It was revealed in patients with acute coronary syndromes that the risk of death was associated with a markedly higher BNP concentration. Such elevated values, if maintained in the serum of patients for 48 hours after myocardial infarction, increase the risk of chronic heart failure or death within a year [104]. Bassan et al. analyzed the data of 631 patients diagnosed in the admission room with chest pain with no ST-segment elevation on the ECG. In the analyzed material, patients diagnosed with myocardial infarction with no ST-segment elevation had significantly higher BNP concentrations on admission compared to those with unstable angina and to those in whom coronary etiology was not confirmed (the median BNP concentrations were, respectively: 203.5, 77.9 and 27.7 pg/ml, p < 0.0001). Patients with positive troponin values on admission demonstrated higher initial BNP concentrations compared to patients with negative initial results. However, no linear correlation was observed between the concentrations of troponin and BNP. In a subgroup of patients with low troponin values (both for the cut-off < 0.28 and 1 ng/ml), high BNP concentrations additionally distinguished patients with a high risk of the development of
myocardial infarction. In multimarker analysis, BNP concentrations above 100 pg/ml were a prognostic marker of myocardial infarction risk, independent of other clinical parameters. The addition of the initial values of necrosis markers to a multimarker model did not increase its predictive power. According to the authors of the study, BNP provides additional prognostic value to traditional markers of necrosis, particularly in the case when the first determinations of the markers are non-diagnostic [105].

Jarai et al., working with patients with unstable angina/non-ST-elevation myocardial infarction and normal Nt-pro BNP concentrations, additionally determined the concentrations of atrial natriuretic factor (Nt-pro ANP), demonstrating that in the investigated group, these concentrations together with troponin were independent prognostic factors of 2-year mortality [106]. Elevated serum ANP concentrations in patients with unstable angina may reflect left ventricular diastolic and increased BNP concentrations – both systolic and diastolic dysfunction [107]. However, further studies should be performed to confirm this phenomenon.

Schnabel et al. assessed 904 patients subjected to coronary angiography and the AtheroGene study. Elevated BNP values were connected with an increased risk of cardiovascular death in follow-up observation, not only in the group of patients with unstable angina, but also with stable angina. This dependency was particularly distinct for the upper quartile of BNP concentrations (3.7-fold risk increase for patients with stable coronary artery disease). Furthermore, an additional consideration of C-reactive protein concentrations in the multimarker model did not improve the model’s prognostic power. The results of this study correlate with those of other similar studies, and broaden the application of BNP onto a group of patients with stable angina [108]. The analysis of BNP concentration in acute myocardial infarction demonstrated its maximal values 21 hours after initial symptoms and moreover, the dependence was observed between maximal BNP concentrations and the concentration of creatinine kinase [109-111].

Schnabel et al. later showed that, if the BNP value of 100 pg/ml was accepted as the cut-off value, patients with higher BNP concentrations had an over 4-fold higher risk of negative events (myocardial infarction, cardiovascular death) as compared to the remaining studied population. In relation to all the analyzed markers (age, gender, acute state markers or left ventricular systolic function), the BNP measurement had the highest accuracy in the prognosis of negative events measured under ROC curve (0.671) [112]. Omland et al. demonstrated that N-terminal pro-B-type natriuretic peptide is a sensitive prognostic marker for short, medium- and long-term mortality in the acute coronary syndromes they investigated [113].
Natriuretic peptides together with nitric oxide inhibit angiotensin, noradrenaline and above all endothelin pressor activity, thereby conditioning the normal vascular wall tone. Factors affecting endothelial balance play this basic role in systemic pressure regulation.

The vascular endothelium, releasing a number of substances of vasodilating activity into the blood flow, such as nitric oxide (NO), prostacyclines, hyperpolarising factor (EDHF), or of vasoconstricting activity, such as thromboxan A2, prostaglandin H2, endothelin (ET-1), is not only a local regulator of vascular wall tone, but also plays an important role in the endogenic system of systemic arterial pressure control. Despite their vasodilating role, natriuretic peptides also have indirect hypotensive activity inhibiting the vasoconstricting effect of noradrenaline, angiotensin II and vasopressin. Furthermore, they weaken the angiotensin II and vasopressin central pressor effect and the central stimulation of the sympathetic system. The influence on the sympathetic system is connected with the intensification of the reflex from the baroreceptors. The reduction of vascular resistance and blood pressure, the increase in the cardiac index, and the decrease in vascular resistance in the pulmonary circulation and right atrium was observed during the venous infusion of BNP. The coronary and renal vessels are particularly sensitive to the vasodilating effect of natriuretic peptides. CNP, synthesized by the endothelium, probably plays an important role in the local vasodilating effect. Unlike other natriuretic peptides, CNP works on the smooth muscles of both venous and arterial vessels [114].

The effect of the same ANP and BNP doses was directly compared in patients with arterial hypertension in the studies carried out by Pigeon et al. The haemodynamic and endocrine influence of natriuretic peptides was assessed. In this study, the effects of equimolal ANP and BNP doses and the two peptides together were compared. The infusion of peptides increased natriuresis over the level observed before their administration, decreased arterial pressure, increased the hematocrit, and inhibited the RAA system and plasma norepinephrine concentration. ANP significantly elevated the plasma and urine second messenger (cGMP) levels relative to BNP. Both increased the norepinephrine concentration by about 30% [115].

Inhibition of the activity of neutral endopeptidase (NEP), which is involved in the elimination of natriuretic peptides, induced sodium-excreting activity in an animal model of arterial hypertension, and in humans. Conversely, sodium excretion and the hypotensive activity of natriuretic peptides is reduced significantly in patients with hypertension, or renal or heart failure. It is supposed that both increased natriuretic peptide metabolism and decreased expression of tissue receptors are the cause.

ET-1 demonstrates the strongest vasoconstrictor and pressor activity. Its increased concentration was observed in malignant hypertension and the pre-
An elevated ET-1 concentration increases central and peripheral sympathetic system tone and potentiates noradrenaline vasoconstricting activity [117]. Thus, it is assumed that a disturbed interaction between ET-1 and the sympathetic nervous system may be one of the factors determining the development of arterial hypertension.

**SEPTIC SHOCK**

BNP is a marker of left ventricular dysfunction. Myocardial dysfunction frequently accompanies severe sepsis and septic shock [118, 119]. Witthaut et al. also confirmed this in their studies [120]. In cases of septic shock, they found a significant increase in ANP (82.7 ± 9.9 vs. 14.9 ± 1.2 pg/ml) and BNP (12.4 ± 3.6 vs. 5.5 ± 0.7 pg/ml). The plasma ANP peaked together with IL-6. The peaks of ANP and IL-6 were significantly correlated (r = 0.73; p < 0.01). The BNP level was inversely correlated to the cardiac index (r = -0.56; p < 0.05). They suggest that BNP reflects left ventricular dysfunction and ANP is related to IL-6 production rather than to cardiovascular dysfunction. Chua et al. described a markedly elevated Nt-pro BNP level in patients with septic shock [121].

**GENETIC ANALYSES IN CORONARY DISEASES**

A lack of the ANP gene was observed to condition the development of sodium-sensitive hypertension, whereas increased expression of this gene in transgenic animals is associated with an excessive decrease in pressure. Studies on ANP gene polymorphism in patients with arterial hypertension resulted in the determination of allelic and genotypic distribution of ANP coding genes' molecular variants. The occurrence of idiopathic hypertension in close connection with the presence of ANP gene polymorphism has been confirmed in clinical trials in humans [122]. A detailed analysis of ANP gene structure allowed the detection of mutation within its coding sequence and 5′ terminus. Increased cGMP release observed in the investigated group led to endothelial imbalance and in consequence to early vascular wall damage [123].

The Scal ANP gene polymorphism: transition T2238 →C leads to the loss of Scal restriction site. Among the patients with coronary disease, the TT genotype was associated with more frequent prevalence of myocardial infarction and a greater number of atherosclerotically changed vessels [124]. A mutation in 341 NPR-A leading to the replacement of isoleucine with methionine in the amino acid chain (Met 341 Ile) was also investigated. The mutation was significantly more frequently observed in the group of patients with myocardial infarction than in the controls [125]. No association was found between BNP gene C 1563 T polymorphism and the development of idiopathic dilated cardiomyopathy [126]. Polymorphism in intron 18 (insertion/deletion of 9 base pairs) and in intron 11 (C 2077 T) is described within the BNP receptor gene (NPR-B). Polymorphism within a 3′ region not undergoing translation (G 2628 A) affects the occurrence of hypertension [127].
CONCLUSIONS

Every year, the depth and breadth of knowledge on the role and activity of natriuretic peptides and endothelins in the human organism is greater. The interactions between these peptides can be described more and more precisely. However, many mechanisms have yet to be elucidated. Explaining the processes taking place in the vascular internal membrane is of particular importance from the point of view of the diagnostics and therapy of cardiovascular diseases. It is of significance for the establishment of pathomechanisms of the numerous pathologies of this system and for the determination of new directions in their therapy [128]. In recent years, the idea of natriuretic peptide application in clinical practice has gained considerable support [129-131]. Unfortunately, the obtained results are not always encouraging [132], and further research is definitely required.

REFERENCES

1. de Bold, A.J., Borenstein, H.B., Veress, A.T. and Sonnenberg, A. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci. 28 (1981) 89-94.
2. Kangawa, K. and Matsuo, H. Purification and complete amino acid sequence of alfa-human atrial natriuretic polypeptide (alfa-hANP). Biochem. Biophys. Res. Commun. 118 (1984) 131-139.
3. Sudoh, T., Kangawa, K., Minamino, N. and Matsuo, H. A new natriuretic peptide in porcine brain. Nature 332 (1988) 78-81.
4. Yasue, H., Yoshimura, M., Sumida, H., Kikuta, K., Kugiyama, K., Jougasaki, M., Ogawa, H., Okumura, K., Mukoyama, M. and Nakao, K. Localisation and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 (1994) 195-203.
5. Barr, C.S., Rhodes, P. and Struthers, A.D. C-type natriuretic peptide. Peptides 17 (1996) 1243-1251.
6. de Lemos, J.A., McGuire, D.K. and Drazner, M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 361 (2003) 316-322.
7. Komatsu, Y., Nakao, K., Suga, S., Ogawa, Y., Mukoyama, M., Arai, H., Shirakami, G., Hosoda, K., Nakagawa, O. and Hama, N. C-type natriuretic peptide in rats and humans. Endocrinology 129 (1991) 1104-1106.
8. Stein, B.C. and Levin, R.I. Natriuretic peptides: Physiology, therapeutic potential and risk stratification in ischemic heart disease. Am. Heart J. 135 (1998) 914-923.
9. Schweitz, H., Vigne, P. and Minier, D. A new member of the natriuretic peptide family is present in the venom of green mamba (dendroaspis angusticeps) J. Biol. Chem. 267 (1992) 13928-13932.
10. Schirger, J.A., Heublein, D.M., Chen, H.H., Lisy, O., Jougasaki, M., Wennberg, P.W. and Burnett, J.C. Jr. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. *Mayo Clin. Proc.* 74 (1999) 126-130.

11. Hickey, K.A., Rubanyi, G., Paul, R.J. and Higsmith, R.F. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. *Am. J. Physiol.* 248 (1985) C550-C556.

12. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. and Masaki, T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 332 (1988) 411-415.

13. Ogawa, K., Oida, A., Sugimura, H., Kaneko, N., Nogi, N., Hasumi, M., Numao, T., Nagao, I. and Mori, S. Clinical significance of blood brain natriuretic peptide level measurement in the detection of heart disease in untreated outpatients-comparison of electrocardiography, chest radiography and echocardiography. *Circ. J.* 66 (2002) 122-126.

14. Cheung, B. and Kumana, C. Natriuretic peptides-relevance in cardiac disease. *JAMA* 280 (1998) 1983-1984.

15. Koskinas, K., Tzellos, T.G., Gougoulias, K., Gougoulias, G., Papakonstantinou, C. and Kouvelas, D. Simvastatin-induced rhabdomyolysis: a case study on clinical-decision making based on the evidence-based medicine approach. *Arch. Med. Sci.* 3 (2007) 267-271.

16. Levin, E.R., Gardner, D.G. and Samson, W.K. Natriuretic peptides-relevance in cardiac disease. *N. Engl. J. Med.* 339 (1998) 321-328.

17. Kalra, P.R., Clague, J.R. and Bolger, A.P. Myocardial production of C-type natriuretic peptide in chronic heart failure. *Circulation* 107 (2003) 571-573.

18. Grabowski, M., Malek, L.A., Karpinski, G, Filipiak, K.J. and Opolski, G. BNP in the differential diagnosis of amiodarone-induced pulmonary toxicity: a case report and review of the literature. *Arch. Med. Sci.* 2 (2006) 131-133.

19. Banach, M., Markuszewski, L., Zasłonka, J., Grzegorczyk, J., Okoński, P. and Jegier, B. The role of inflammation in the pathogenesis of atherosclerosis. *Przegl. Epidemiol.* 58 (2004) 663-670.

20. Piechota, M, Banach, M, Irzmański, R, Piechota-Urbańska, M, Kowalski, J. and Pawlicki, L. NT-proBNP levels correlate with organ failure in septic patients – preliminary report. *Postepy Hig. Med. Dosw. (Online)* 60 (2006) 632-636.

21. Brown, A.M., Sease, K.L., Robey, J.L., Shofer, F.S. and Hollander, J.E. The impact of B-type natriuretic peptide in addition to troponin I, creatine kinase-MB, and myoglobin on the risk stratification of emergency department chest pain patients with potential acute coronary syndrome. *Ann. Emerg. Med.* 49 (2007) 153-163.

22. Irzmański, R., Banach, M., Piechota, M., Barylski, M., Serwa-Stepień, E., Cierniewski, C., Jegier, B., Kowalski, J. and Pawlicki, L. BNP concentration
in patients with mitral stenosis. Dependence on selected morphological parameters. Arch. Med. Sci. 2 (2006) 159-163.

23. Brunner-La Rocca, H.P., Kiowski, W., Ramsay, D. and Sütsch, G. Therapeutic benefits of increasing natriuretic peptides levels. Cardiovasc. Res. 51 (2001) 510-520.

24. Gutkowska, J., Antunes-Rodrigues, J. and McCann, S.M. Atrial natriuretic peptide in brain and pituitary gland. Physiol. Rev. 77 (1997) 465-515.

25. Pidgeon, G.B., Richards, A.M. and Nichols, M.G. Differing metabolism and bioactivity of atrial and brain natriuretic peptide in essential hypertension. Hypertension 27 (1996) 906-913.

26. Irzmanski, R., Banach, M., Piechota, M., Kowalski, J., Barylski, M., Cierniewski, C. and Pawlicki, L. Atrial, Brain Natriuretic Peptide and Endothelin-1 concentration in patients with idiopathic arterial hypertension. The dependence on the selected morphological parameters. Clin. Exp. Hypertens. 29 (2007) 149-164.

27. de Lemos, J.A. and Morrow, D.A. Use of natriuretic peptides in clinical decision-making for patients with non-ST-elevation acute coronary syndromes. Am. Heart J. 153 (2007) 450-453.

28. Kowalski, J., Banach, M., Barylski, M., Irzmanski, R. and Pawlicki, L. Carvedilol modifies antioxidant status of patients with stable angina. Cell. Mol. Biol. Lett. 13 (2008) in press.

29. Kapoun, A.M., Liang, F., O'Young, G., Damm, D.L., Quon, D., White, R.T., Munson, K., Lam, A., Schreiner, G.F. and Protter, A.A. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ. Res. 94 (2004) 453-461.

30. Dietz, J.R. Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc. Res. 68 (2005) 8-17.

31. McDowell, G., Patterson, C., Maguire, S., Shaw, C., Nicholls, D.P. and Hall, C. Variability of Nt-proANP and C-ANP. Eur. J. Clin. Invest. 32 (2002) 545-548.

32. Wittthaut, R., Busch, C., Fraunberger, P., Walli, A., Seidel, D., Pilz, G., Stuttmann, R., Speichermann, N., Verner, L. and Werdan, K. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intens. Care Med. 29 (2003) 1696-1702.

33. Maisel, A.S., Clopton, P., Krishnaswamy, P., Nowak, R.M., McCord, J., Hollander, J.E., Duc, P., Omland, T., Storrow, A.B., Abraham, W.T., Wu, A.H., Steg, G., Westheim, A., Knudsen, C.W., Perez, A., Kazanegra, R., Bhalla, V., Herrmann, H.C., Aumont, M.C. and McCullough, P.A. BNP Multinational Study Investigators. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am. Heart J. 147 (2004) 1078-1084.
34. Clerico, A., Lervasi, G. and Mariani, G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm. Metab. Res. 31 (1999) 487-498.
35. Cosin Aguilar, J., Hernandez Martinez, A., Diez Gil, J.L., Capdevila Carbonell, C., Salvador Sanz, A., Diago Torrent, J.L., Rivera Otero, M., Paya Serrano, R., Bertomeu Martinez, V., Sogorb Garri, F., Jordan Torrent, A., Mainar Latorre, L., Grau Jornet, G., Marti Llinares, S. and Miro Palau, V. Grupo de Estudio de la Disfuncion Ventricular Izquierda en la Comunidad. Value of NTproBNP concentration in an out-of-hospital adult population. Rev. Esp. Cardiol. 56 (2003) 236-244.
36. Bozkurt, B. and Mann, D.L. Use of Biomarkers in the Management of Heart Failure. Are We There Yet? Circulation 107 (2003) 1231-233.
37. Irzmanski, R., Barylski, M., Banach, M., Piechota, M., Kowalski, J., Cierniewski, C. and Pawlicki, L. The concentration of atrial and brain natriuretic peptide in patients with idiopathic arterial hypertension. Med. Sci. Monit. 13 (2007) CR449-456.
38. Rubanyi, G.M. and Polokoff, M.A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 46 (1994) 325-415.
39. Goto, K. Basic and therapeutic relevance of endothelin-mediated regulation. Biol. Pharm. Bull. 24 (2001) 1219-1230.
40. Benigni, A. and Remuzzi, G. Endothelin antagonists. Lancet 353 (1999) 133-138.
41. Inoue, A., Yanagisawa, M., Kimura, S. Kasuya, Y., Miyachi, T., Goto, K. and Masaki, T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA 86 (1989) 2863-2867.
42. Ducancel, F. Endothelin-like peptides. Cell Mol. Life Sci. 62 (2005) 2828-2839.
43. Kedzierski, R.M. and Yanagisawa, M. Endothelin system: the double-edged sword in health and disease. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 851-876.
44. Pawlawska, Z., Jerczynska, H., Szemraj, J., Baranska, P., Swiatkowska, M. and Cierniewski, C.S. Natriuretic peptides reduce plasminogen activator inhibitor-1 expression in human endothelial cells. Cell Mol. Biol. Lett. 7 (2002) 1153-1157.
45. Ohnmishi, M, Wada, A, Tsutamoto, T, Sawaki, M., Fujii, M., Matsumoto, T. and Kinoshita, M. Significant role of endothelin-A and endothelin-B receptor in renal function in congestive heart failure. J. Cardiovasc. Pharmacol. 36 (5 Suppl.1) (2000) 44-49.
46. Wang, J., Chiou, W.J., Gagne, G.D. and Wu-Wong, J.R. Internalization of type-A endothelin receptor. J. Cardiovasc. Pharmacol. 36 (5 Suppl.1) (2000) 61-65.
47. Iglarz, M. and Schiffrin, E.L. Role of endothelin-1 in hypertension. Curr. Hypertens. Rep. 5 (2003) 144-148.
48. Haynes, W.G., Ferro, C.J., O’Kane, K.P., Somerville, D., Lomax, C.C. and Webb, D.J. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. *Circulation* **93** (1996) 1860-1870.

49. Irzmański, R., Serwa-Stepień, E., Barylski, M., Banach, M., Kowalski, J. and Pawlicki, L. Endothelial dysfunction in hypertension. The role of natriuretic peptides and endothelin. *Kardiol. Pol.* **63** (Supl. 2) (2005) 457-461.

50. Schiffrin, E.L., Intengan, H.D., Thibault, G. and Touyz, R.M. Clinical significance of endothelin in cardiovascular disease. *Curr. Opin. Cardiol.* **12** (1997) 354-367.

51. Burrell, K.M., Molenaar, P., Dawson, P.J. and Kauman, A.J. Contractile and arrhythmic effect of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. *J. Pharmacol. Exp. Ther.* **292** (2000) 449-459.

52. Saetrum Opgaard, O., Möller, S., de Vries, R., Edvinsson, L. and Saxena, P.R. Positive inotropic responses mediated by endothelin ET (A) and ET (B) receptors in human myocardial trabecule. *Clin. Sci. (Lond.)* **99** (2000) 161-168.

53. Fabris, B., Chen, B., Pupic, V., Perich, R. and Johnston, C.I. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue. *J. Cardiovasc. Pharmacol.* **15** (Suppl. 2) (1990) 56-59.

54. Weber, K.T. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. *Semin. Nephrol.* **17** (1997) 461-464.

55. Benigni, A., Perico, G. and Remuzzi, G. Endothelin antagonists and renal protection. *J. Cardiovasc. Pharmacol.* **35** (4 Suppl. 2) (2000) 75-79.

56. Bassenge, E. Endothelial function in different organs. *Prog. Cardiovasc. Dis.* **39** (1996) 209-228.

57. Dries, D.L. Relevance of molecular forms of brain natriuretic peptide for natriuretic peptide research. *Hypertension* **49** (2007) 971-973.

58. Hama, N., Itoh, H., Shirakami, G., Nakagawa, O., Suga, S., Ogawa, Y., Masuda, I., Nakanishi, K., Yoshimasa, T. and Hashimoto, Y. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. *Circulation* **92** (1995) 1558-1564.

59. Peacock, W.F. The B-type natriuretic peptide assay: A rapid test for heart failure. *Cleve. Clin. J. Med.* **69** (2002) 243-251.

60. Qi, W., Mathisen, P., Kjekshus, J., Simonsen, S., Bjornerheim, R., Endresen, K. and Hall, C. Natriuretic peptides in patients aortic stenosis. *Am. Heart J.* **142** (2001) 725-732.

61. Nagaya, N., Nishikimi, T., Uematsu, M., Satoh, T., Kyotani, S., Sakamaki, F., Kakishita, M., Fukushima, K., Okano, Y., Nakanishi, N., Miyatake, K. and Kangawa, K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *Circulation* **102** (2000) 865-870.

62. Fagan, K.A., McMurtry, I.F. and Rodman, D.M. Role of endothelin-1 in lung disease. *Respir. Res.* **2** (2001) 90-101.
63. Teder, P. and Noble, P.W. A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis. *Am. J. Respir. Cell Mol. Biol.* **23** (2000) 19-26.

64. Thomson, A.B., Keelan, M. and Thiesen, A. Small bowel review: normal physiology part 2. *Dig. Dis. Sci.* **46** (2001) 2588-2607.

65. Zuccarello, M. Endothelin: the “prime suspect” in cerebral vasospasm. *Acta Neurochir. Suppl.* **77** (2001) 61-65.

66. Saito, Y., Nakao, K., Nishimura, K., Sugawara, A., Okumura, K., Obata, K., Sonoda, R., Ban, T., Yasue, H. and Amura, H. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. *Circulation* **76** (1987) 115-124.

67. Saito, Y., Nakao, K., Nishimura, K., Sugawara, A., Okumura, K., Obata, K., Sonoda, R., Ban, T., Yasue, H. and Amura, H. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. *Circulation* **76** (1987) 115-124.

68. Tsutamoto, T., Wada, A., Maeda, K., Hisanaga, T., Mabuchi, N., Hayashi, M., Ohnishi, M., Sawaki, M., Fujii, M., Horie, H., Sugimoto, Y. and Kinoshita, M. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. *Eur. Heart J.* **19** (1999) 1799-1807.

69. Maisel, A.S., Krishnaswamy, P., Nowak, R.M., McCord, J., Hollander, J.E., Duc, P., Omland, T., Storrow, A.B., Abraham, W.T., Wu, A.H., Clopton, P., Steg, P.G., Westheim, A., Knudsen, C.W., Perez, A., Kazanegra, R., Herrmann, H.C., McCullough, P.A. and the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N. Engl. J. Med.* **347** (2002) 161-167.

70. Cosin Aguilar, J., Rodriguez Padial, L., Zamorano Gomez, J.L., Aristegui Urrestarazu, A., Armada Pelaez, B., Hernandez Martinez, A., Aguilar Llopis, A. and Masramon Morell, X. Coronary risk differences in hypertensive patients of different autonomous communities. CORONARY study. *Rev. Clin. Esp.* **204** (2004) 614-625.

71. McDonagh, T.A., Robb, S.D., Murdoch, D.R., Morton, J.J., Ford, I., Morrison, C.E., Tunstall-Pedoe, H., McMurray, J.J. and Dargie, H.J. Biochemical detection of left ventricular systolic dysfunction. *Lancet* **351** (1998) 9-13.

72. Dao, Q., Krishnaswamy, P., Kazanegra, R., Harrison, A., Amirnovin, R., Lenert, L., Clopton, P., Alberto, J., Hlavin, P. and Maisel, A.S. Utility of B-type natriuretic peptide (BNP) in the diagnosis of CHF in an urgent care setting. *J. Am. Coll. Cardiol.* **37** (2001) 379-385.

73. Cocco, G. and Chu, D. Weight reduction decreases NT-proBNP levels in obese coronary patients with chronic diastolic heart failure. *Arch. Med. Sci.* **3** (2007) 112-116.

74. Cowie, M.R., Struthers, A.D., Wood, D.A., Coats, A.J., Thompson, S.G., Poole-Wilson, P.A. and Sutton, G.C. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. *Lancet* **350** (1997) 1349-1352.
75. Berger, R., Huelsman, M., Strecker, K., Bojic, A., Moser, P., Stanek, B. and Pacher, R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. *Circulation* **105** (2002) 2392-2397.

76. Tsutamoto, T., Wada, A., Maeda, K., Hisanaga, T., Maeda, Y., Fukai, D., Ohnishi, M., Sugimoto, Y. and Kinoshita, M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. *Circulation* **96** (1997) 509-516.

77. Collins, S.P., Ronan-Bentle, S. and Storrow, A.B. Diagnostic and prognostic usefulness of natriuretic peptides in Emergency Department patients with dyspnea. *Ann. Emerg. Med.* **41** (2003) 532-545.

78. Maisel, A.S., Koon, J., Krishnaswamy, P., Kazenegra, R., Clopton, P., Gardetto, N., Morrisey, R., Garcia, A., Chiu, A. and De Maria, A. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. *Am. Heart J.* **141** (2001) 367-374.

79. Kimura, K., Yamaguchi, Y., Horii, M., Kawata, H., Yamamoto, H., Uemura, S. and Saito, Y. ANP is cleared much faster than BNP in patients with congestive heart failure. *Eur. J. Clin. Pharmacol.* **63** (2007) 699-702.

80. Cheng, V., Kazanegra, R., Garcia, A., Lenert, L., Krishnaswamy, P., Gardetto, N., Clopton, P. and Maisel, A. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. *J. Am. Coll. Cardiol.* **37** (2001) 386-391.

81. Kawakami, R., Saito, Y., Kishimoto, I., Harada, M., Kuwahara, K., Takahashi, N., Nakagawa, Y., Nakamichi, M., Tanimoto, K., Usami, S., Yasuno, S., Kinoshita, H., Chusho, H., Tamura, N., Ogawa, Y. and Nakao, K. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. *Circulation* **110** (2004) 3306-3312.

82. Greig, D., Castro, P., Ferrada, M., Lim, J., Lopez, C., Braun, S., Cordova, S. and Salazar, M. Brain natriuretic peptide in primary pulmonary hypertension. *Rev. Med. Chil.* **134** (2006) 299-304.

83. Piechota, M., Banach, M., Irzmanski, R., Barylski, M., Piechota-Urbanska, M., Kowalski, J. and Pawlicki, L. Plasma endothelin-1 levels in septic patients. *J. Intensive Care Med.* **22** (2007) 232-239.

84. Maeda, K., Tsutamoto, T., Wada, A., Hisanaga, T. and Kinoshita, M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. *Am. Heart J.* **135** (1998) 823-832.

85. Emdin, M., Passino, C., Prontera, C., Iervasi, A., Ripoli, A., Masini, S., Zucchelli, G.C. and Clerico, A. Cardiac natriuretic hormones, neuro-
hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin. Chem. Lab. Med. 42 (2004) 627-636
86. McKinsey, T.A. and Nolson, E.N. Cardiac hypertrophy: sorting out the circuitry. Curr. Opin. Genet. Dev. 9 (1999) 267-274.
87. Piechota, M., Banach, M., Irzmański, R., Misztal, M., Rysz, J., Barylski, M., Piechota-Urbańska, M., Kowalski, J. and Pawlicki, L. N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients. Cell. Mol. Biol. Lett. 12 (2007) 162-175.
88. Gardner, R.S., Ozalp, F., Murday, A.J. Robb, S.D. and McDonagh, T.A. N-terminal brain natriuretic peptide: the new gold standard in predicting mortality in patients with advanced heart failure. Eur. Heart J. 24 (2003) 1735-1743.
89. Hodges, M., Bailey, J.J. and Church, T.R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 107 (2003) e13.
90. Hammerer-Lercher, A., Ludwig, W., Falkensammer, G., Muller, S., Neubauer, E., Puschendorf, B., Pachinger, O. and Mair, J. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin. Chem. 50 (2004) 1174-1183.
91. Clerico, A. and Emdin, M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin. Chem. 50 (2004) 33-50.
92. Remme, W.J. and Swedberg, K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 22 (2001) 1527-1560.
93. Jourdain, P., Funck, F. and Bellorini, M. Brain natriuretic peptide and heart failure, from bench to bedside. Ann. Cardiol. Angeiol. (Paris) 53 (2004) 193-199.
94. Anand, I.S., Fisher, L.D., Chiang, Y.T. Latini, R., Masson, S., Maggioni, A.P., Glazer, R.D., Tognoni, G., Cohn, J.N. and Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in Val-HeFT. Circulation 107 (2003) 1278-1283.
95. Troughton, R.W., Frampton, C.M., Yandle, T.G. Espiner, E.A., Nicholls, M.G. and Richards, A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130.
96. Brunner-La Roca, H.P., Kaye, D.M., Woods, R.L. Hastings, J. and Esler, M.D. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared to control subjects. J. Am. Coll. Cardiol. 37 (2001) 1221-1227.
97. Abraham, W.T., Lowes, B.D., Ferguson, D.A., Odom, J., Kim, J.K., Robertson, A.D., Bristow, M.R. and Schrier, RW. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with advanced hemodynamically decompensated heart failure. J. Card. Fail. 4 (1998) 37-44.
98. Tepper, D. Frontiers in congestive heart failure: Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting. Congest. Heart Fail. 7 (2001) 330.

99. Banach, M., Goch, A., Misztal, M., Rysz, J., Barylski, M., Jaszewski, R. and Goch, J.H.. Low output syndrome following aortic valve replacement. Predictors and prognosis. Arch. Med. Sci. 3 (2007) 117-122.

100. Banach, M., Drożdż, J., Okoński, P. and Rysz, J. Immunological aspects of the statins’ function in patients with heart failure. A raport from the Annual Conference of ESC – Heart Failure 2005. Cell. Mol. Immunol. 2 (2005) 433-437.

101. Irzmański, R., Piechota, M., Barylski, M., Banach, M., Kowalski, J., Serwa-Stepień, E., Drożdż, J. and Pawlicki, L. NT-proBNP in patients after acute coronary syndrome with ST segment elevation subjected to early posthospitalization cardiologic rehabilitation. Arch. Med. Sci. 2 (2006) 262-267.

102. Sabatine, M.S., Morrow, D.A., de Lemos, J.A., Omland, T., Desai, M.Y., Tanasijevic, M., Hall, C., McCabe, C.H. and Braunwald, E. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J. Am. Coll. Cardiol. 44 (2004) 1988-1995.

103. James, S.K., Lindahl, B., Siegbahn, A., Stridsberg, M., Venge, P., Armstrong, P., Barnathan, E.S., Califf, R., Topol, E.J., Simoons, M.L. and Wallentin, L. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108 (2003) 275-281.

104. de Lemos, J.A., Morrow, D.A., Bentley, J.H., Omland, T., Sabatine, M.S., McCabe, C.H., Hall, C., Cannon, C.P. and Braunwald, E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. 345 (2001) 1014-1021.

105. Bassan, R., Potsch, A., Maisel, A., Tura, B., Villacorta, H., Nogueira, M.V., Campos, A., Gamarski, R., Masetto, A.C. and Moutinho, M.A. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. Eur. Heart J. 26 (2005) 234-240.

106. Jarai, R., Iordanova, N., Jarai, R., Raffetseder, A., Woloszczuk, W., Gyöngyösi, M., Geyer, G., Wojta, J. and Huber K. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Eur. Heart J. 26 (2005) 250-256.

107. Skrzypiec, M. and Spring, A. Plasma levels of atrial (ANP) and brain (BNP) natriuretic peptides in patients with unstable angina pectoris. Mag. Lek. Rodz. 12 (2004) (http://www.medicus.com.pl/hr/hr_arch_2004-12.html)

108. Schnabel, R., Rupprecht, H.J., Lackner, K.J., Lubos, E., Bickel, C., Meyer, J., Münzel, T., Cambien, F., Tietz, L. and Blankenberg, S.; AtheroGene
Investigators. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur. Heart J. 26 (2005) 241-249.

109. Kowalski, J., Banach, M., Barylski, M., Grycewicz, J., Irzmanski, R. and Pawlicki, L. Neutrophil superoxide an ion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J. Cardiovasc. Pharmacol. 48 (2006) 143-147.

110. Heusch, P., Skyschally, A., Leineweber, K., Haude, M., Erbel, R. and Heusch, G. The interaction of coronary microembolization and ischemic preconditioning: A third window of cardioprotection through TNF-alpha. Arch. Med. Sci. 3 (2007) 83-92.

111. Piechota, M., Irzmański, R., Banach, M., Kowalski, J. and Pawlicki, L. Impedance cardiography in haemodynamic monitoring of septic patients: a prospective study. Arch. Med. Sci. 3 (2007) 145-151.

112. Schnabel, R., Lubos, E., Rupprecht, H.J., Espinola-Klein, C., Bickel, C., Lackner, K.J., Cambien, F., Tiret, L., Munzel, T. and Blankenberg, S. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina. results from the AtheroGene Study. J. Am. Coll. Cardiol. 47 (2006) 552-558.

113. Omland, T., Persson, A., Ng, L., O’Brien, R., Karlsson, T., Herlitz, J., Hartford, M. and Caidahl, K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918.

114. Schaller, B.J. The role of endothelin in stroke: Experimental data and underlying pathophysiology. Arch. Med. Sci. 2 (2006) 146-158.

115. Pidgeon, G.B., Richards, A.M. and Nichols, M.G. Differing metabolism and bioactivity of atrial and brain natriuretic peptide in essential hypertension. Hypertension 27 (1996) 906-913.

116. Gryglewski, R.J. Interactions between endothelial mediators. Pharmacol. Toxicol. 77 (1995) 1-9.

117. Ferro, C.J. and Webb, D.J. Endothelial dysfunction and hypertension. Drugs 53 (Suppl. 1) 30-41.

118. Castillo J.R., Zagler, A., Carrillo-Jimenez, R. and Hennekens, C.H. Brain natriuretic peptide: a potential marker for mortality in septic shock. Int. J. Infect. Dis. 8 (2004) 271-274.

119. Charpentier, J., Luyt, C.E., Fulla, Y., Vinsonneau, C., Cariou, A., Grabar, S., Dhainaut, J.F., Mira, J.P. and Chiche, J.D. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit. Care Med. 32 (2004) 660-665.

120. Witthaut, R. Science review: natriuretic peptides in critical illness. Crit. Care 8 (2004) 342-349.

121. Chua, G. and Kang-Hoe, L. Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit. Care 8 (2004) 248-250.
122. Kato, N., Sugiyama, T., Morita, H., Nabika, T., Kurihara, H., Yamori, Y. and Yazaki, Y. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin. Sci. (London) 98 (2000) 251-258.

123. Rubattu, S., Giliberti, R., Ganten, U. and Volpe, M. A differential brain atrial natriuretic peptide expression co-segregates with occurrence of early stroke in the stroke prone phenotype of spontaneously hypertensive rat. J. Hypertens. 17 (1999) 1849-1852.

124. Gruchala, M, Ciecierewicz, D, Wasag, B, Targonski, R., Dubaniewicz, W., Nowak, A., Sobczewski, W., Oehman, K., Romanowski, P., Limon, J. and Rynkiewicz, A. Association of the Scal atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am. Heart J. 145 (2003) 125-131.

125. Nakayama, T., Soma, M., Saito, S., Honye, J., Sato, M., Aoi, N., Kosuge, K., Haketa, A., Kanmatsuse, K. and Kokubun, S. Missense mutation of exon 3 in the type A human natriuretic peptide receptor gene is associated with myocardial infarction. Med. Sci. Monit. 9 (2003) CR505-CR510.

126. Tiret, L., Mallet, C., Poirier, O., Nicaud, V., Millaire, A., Bouhour, J.B., Roizes, G., Desnos, M., Dorent, R., Schwartz, K., Cambien, F. and Komajda, M. Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J. Am. Coll. Cardiol. 35 (2000) 29-35.

127. Ono, K., Mannami, T., Baba, S., Yasui, N., Ogihara, T. and Iwai, N. A single-nucleotide polymorphism in C-type natriuretic peptide gene may be associated with hypertension. Hypertens. Res. 25 (2002) 727-730.

128. Irzmański, R., Piechota, M., Barylski, M., Banach, M., Gławęda, B., Kowalski, J., Ciernciewski, C., Kośmider, M. and Pawlicki, L. Dynamics of changes of the BNP concentration in patients with stable angina pectoris qualified for PTCA. Dependence on the selected morphological and haemodynamic parameters. Arch. Med. Sci. 2 (2006) 15-19.

129. Topol, E.J. Nesiritide – not verified. N. Engl. J. Med. 353 (2005) 113-116.

130. Sackner-Bernstein, J.D., Skopicki, H.A. and Aaronson, K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491.

131. Sackner-Bernstein, J.D., Kowalski, M., Fox, M. and Aaronson, K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905.

132. Meyer, M., Pfarr, E., Schirmer, G., Überbacher, H.J., Schope, K., Bohn, E., Fluge, T., Mentz, P., Scigalla, P. and Forssmann, W.G. Therapeutic use of the natriuretic peptide ularitide in acute renal failure. Ren. Fail. 21 (1999) 85-100.